Estella Matutes

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis
    P D Thornton
    Section of Haemato oncology, Institute of Cancer Research, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Leuk Res 29:389-95. 2005
  2. ncbi Case 33. Diagnostic difficulty in a patient with acute leukemia
    Allison C Y Tso
    Department of Haematology, Hammersmith Hospital, London, UK
    Leuk Lymphoma 48:177-9. 2007
  3. ncbi Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
    E Matutes
    Section of Haemato oncology, Institute of Cancer Research, London, UK
    Leukemia 22:487-95. 2008
  4. ncbi Differential diagnosis in chronic lymphocytic leukaemia
    Estella Matutes
    Haemato oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 20:367-84. 2007
  5. ncbi Splenic marginal zone lymphoma with and without villous lymphocytes
    Estella Matutes
    Haemato Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London, SW3 6JJ, UK
    Curr Treat Options Oncol 8:109-16. 2007
  6. pmc Adult T-cell leukaemia/lymphoma
    E Matutes
    Haemato Oncology Unit, The Institute of Cancer Research Royal Marsden NHS Trust, London, UK
    J Clin Pathol 60:1373-7. 2007
  7. doi Diagnostic issues in chronic lymphocytic leukaemia (CLL)
    Estella Matutes
    Section of Haemato Oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 23:3-20. 2010
  8. doi Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification
    Estella Matutes
    Department of Haemato Oncology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Blood 117:3163-71. 2011
  9. ncbi Immunophenotyping and differential diagnosis of hairy cell leukemia
    Estella Matutes
    Department of Haemato Oncology, The Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London, SW3 6JJ, UK
    Hematol Oncol Clin North Am 20:1051-63. 2006
  10. ncbi The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients
    E Matutes
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital NHS Trust, Fulham Road, London SW3 6JJ, UK
    Leuk Lymphoma 45:2007-15. 2004

Detail Information

Publications101 found, 100 shown here

  1. ncbi Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis
    P D Thornton
    Section of Haemato oncology, Institute of Cancer Research, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Leuk Res 29:389-95. 2005
    ..We suggest that the relatively high incidence of transformation in this series may be due to immunosuppression mainly related to fludarabine, although other agents and prior therapies may have also contributed...
  2. ncbi Case 33. Diagnostic difficulty in a patient with acute leukemia
    Allison C Y Tso
    Department of Haematology, Hammersmith Hospital, London, UK
    Leuk Lymphoma 48:177-9. 2007
    ..A provisional diagnosis of acute myeloid leukemia, FAB type M2, was made in a 24-year-old woman. Immunophenotyping led to reassessment of the diagnosis...
  3. ncbi Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
    E Matutes
    Section of Haemato oncology, Institute of Cancer Research, London, UK
    Leukemia 22:487-95. 2008
    ....
  4. ncbi Differential diagnosis in chronic lymphocytic leukaemia
    Estella Matutes
    Haemato oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 20:367-84. 2007
    ..Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy...
  5. ncbi Splenic marginal zone lymphoma with and without villous lymphocytes
    Estella Matutes
    Haemato Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London, SW3 6JJ, UK
    Curr Treat Options Oncol 8:109-16. 2007
    ....
  6. pmc Adult T-cell leukaemia/lymphoma
    E Matutes
    Haemato Oncology Unit, The Institute of Cancer Research Royal Marsden NHS Trust, London, UK
    J Clin Pathol 60:1373-7. 2007
    ..Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients...
  7. doi Diagnostic issues in chronic lymphocytic leukaemia (CLL)
    Estella Matutes
    Section of Haemato Oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 23:3-20. 2010
    ..In atypical CLL, histology and/or molecular genetics may be required to exclude other B-cell disorders...
  8. doi Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification
    Estella Matutes
    Department of Haemato Oncology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Blood 117:3163-71. 2011
    ..Age, Ph(+), and AML therapy were predictors for poor outcome (P < .001; P = .002; P = .003). MPAL is confirmed to be a poor-risk disease. Adults and Ph(+) patients should be considered for transplantation in first remission...
  9. ncbi Immunophenotyping and differential diagnosis of hairy cell leukemia
    Estella Matutes
    Department of Haemato Oncology, The Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London, SW3 6JJ, UK
    Hematol Oncol Clin North Am 20:1051-63. 2006
    ..Immunophenotyping is an essential tool for the diagnosis of these two disorders, for monitoring and assessing response to therapy, and for distinguishing them from other B-cell malignancies...
  10. ncbi The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients
    E Matutes
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital NHS Trust, Fulham Road, London SW3 6JJ, UK
    Leuk Lymphoma 45:2007-15. 2004
    ..Splenectomy is a useful treatment option in this group of patients...
  11. ncbi B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia
    Rosa Ruchlemer
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Br J Haematol 125:330-6. 2004
    ..These cases illustrate the importance of tissue diagnosis with cyclin D1 staining and fluorescence in situ hybridization analysis in B-cell leukaemia with prolymphocytic features...
  12. ncbi The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes
    Ilaria del Giudice
    Academic Department of Hematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Haematologica 89:303-8. 2004
    ..The aim of the study was to investigate the diagnostic value of CD123 expression in B-cell disorders with circulating hairy and villous lymphocytes...
  13. ncbi Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings
    Caroline L Alvares
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London SW3 6JJ, UK
    Leuk Lymphoma 45:769-75. 2004
    ..These cases serve to highlight the biological and cytogenetic heterogenity of DLBL and emphasize the need for complementary investigations in the characterization of this entity...
  14. ncbi T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature
    Nnenna Osuji
    Section of Haemato oncology, Institute of Cancer Research, London, United Kingdom
    Cancer 107:570-8. 2006
    ..To the authors' knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia. Available data are limited by patient numbers and coexisting pathologies...
  15. ncbi Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
    Hematol J 5:47-54. 2004
    ..DNA sequencing adds little to these methods in identifying the population at risk...
  16. ncbi ATM mutations are rare in familial chronic lymphocytic leukemia
    Martin R Yuille
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 100:603-9. 2002
    ..Common ATM missense mutations were not overrepresented. The data support previous observations that ATM mutation is associated with B-CLL. However, ATM mutations do not account for familial clustering of the disease...
  17. doi Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Mol Genet 19:1840-5. 2010
    ..These four SNPs map to a 3 kb region of the 3'-UTR of IRF4, consistent with the causal basis of the association being mediated through differential IRF4 expression...
  18. ncbi Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients
    Nilima Parry-Jones
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Br J Haematol 120:759-64. 2003
    ..001 for SLVL deaths). We conclude that SLVL is mainly a disease of the elderly with a relatively benign course but, when treatment is required, splenectomy is beneficial...
  19. ncbi Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment
    Nnenna Osuji
    Section of Haemato oncology, Department of Histopathology, Institute of Cancer Research, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom
    Leuk Res 29:225-8. 2005
    ..We highlight the resistant nature of the LGL clone and discuss the relative merits of immunomodulatory type therapy in this disease...
  20. ncbi CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia
    Patrick D Thornton
    1Academic Department of Haematology and Cytogenetics, Institute of Cancer Research and Royal Marsden NHS Trust, London, UK
    Hematol J 5:145-51. 2004
    ..We conclude that 7% may be a more useful threshold for disease progression than higher values of CD38...
  21. ncbi Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes
    Alicja M Gruszka-Westwood
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research Royal Marsden NHS Trust, London, United Kingdom
    Genes Chromosomes Cancer 36:57-69. 2003
    ..The presence of a high incidence of abnormalities in the established hotspot areas and in particular the finding of biallelic deletions is indicative of the existence of genes important for the pathogenesis of SLVL in these areas...
  22. doi Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk
    Dalemari Crowther-Swanepoel
    Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 42:132-6. 2010
    ..2 (rs783540, CPEB1; OR = 1.18; P = 3.67 x 10(-6)) and 18q21.1 (rs1036935; OR = 1.22; P = 2.28 x 10(-6)). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy...
  23. ncbi Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia
    Vasantha Brito-Babapulle
    FRC Path, Academic Department of Hematology and Cytogenetics, Royal Marsden NHS Trust Institute of Cancer Research, 203, Fulham Road, London SW3 6JJ, UK
    Haematologica 87:357-62. 2002
    ....
  24. ncbi Diagnostic significance of CD20 and FMC7 expression in B-cell disorders
    Julio Delgado
    Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, Institute of Cancer Research, London, England
    Am J Clin Pathol 120:754-9. 2003
    ..FMC7 is of greater diagnostic value than CD20 for distinguishing CLL from other B-cell disorders; we recommend its continued use for this purpose...
  25. pmc Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry
    P Jain
    Department of Academic Haematology and Cytogenetics, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    J Clin Pathol 55:940-5. 2002
    ..To describe and revise a flow cytometric assay for evaluating cyclin D1 overexpression in B cell lymphoproliferative disorders (B-LPDs)...
  26. doi Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL)
    M Mansour Ceesay
    Department of Haematological Medicine, King s College Hospital NHS Foundation Trust and King s College London, London, UK
    Leuk Res 36:857-61. 2012
    ..In conclusion CHOP-Z is safe and in those who achieve a complete response it was associated with prolonged overall survival...
  27. ncbi Causation of chronic lymphocytic leukemia--insights from familial disease
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Leuk Res 27:871-6. 2003
    ..Here, we review the current status of knowledge about inherited susceptibility to CLL...
  28. ncbi Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia
    Rosa Ruchlemer
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Br J Haematol 118:952-8. 2002
    ..Differences seen between MCL and CLL in spleen size, and in response of the leucocytosis suggest a central role for the spleen in the evolution of MCL with leukaemia...
  29. ncbi Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A
    Manal O Elnenaei
    Academic Department of Haematology and Cytogenetics, The Institute of Cancer Research and Royal Marsden Hospital Trust, 203 Fulham Road, London SW3 6JJ, UK
    Haematologica 88:529-37. 2003
    ....
  30. doi Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation
    Hannah C Rudenko
    Section of Haemato oncology, The Institute of Cancer Research ICR, Sutton, Surrey, London, UK
    Leuk Lymphoma 49:1879-86. 2008
    ..02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial...
  31. ncbi p53 abnormalities in splenic lymphoma with villous lymphocytes
    A M Gruszka-Westwood
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research/Royal Marsden NHS Trust, Fulham Rd, London, SW3 6JJ United Kingdom
    Blood 97:3552-8. 2001
    ..Although p53 abnormalities are infrequent in SLVL, they underlie a more aggressive disease course and poor prognosis. (Blood. 2001;97:3552-3558)..
  32. ncbi CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab
    N Osuji
    Section of Haemato oncology, Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
    Leuk Lymphoma 46:723-7. 2005
    ..The strong and consistent expression of CD52 shown here highlights the potential role of alemtuzumab in the treatment of refractory T-cell LGL leukemia and possibly aggressive NK cell leukemia...
  33. doi Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients
    Saeed Al-Shieban
    Department of Histopathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, London, and Imperial College London, UK
    Br J Haematol 154:466-70. 2011
    ..This study provides a practical strategy to distinguish haematogones from B-ALL cells in BMTB...
  34. ncbi Granulomatous slack skin disease--disease features and response to pentostatin
    Nnenna Osuji
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, UK
    Br J Haematol 123:297-304. 2003
    ..The patient has twice achieved a good response to pentostatin after failure of combination chemotherapy. This is the first report of the successful use of the purine analogue pentostatin in the management of GSSD...
  35. ncbi Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review
    Nnenna Osuji
    Section of Haemato oncology, Royal Marsden Hospital Foundation Trust Institute of Cancer Research, London UK
    Am J Surg Pathol 29:935-41. 2005
    ....
  36. ncbi CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease
    Mariano P Scolnik
    Inmunología Oncológica, IIHEMA, Academia Nacional de Medicina de, Buenos Aires, Argentina
    Leuk Res 26:615-9. 2002
    ..Our results indicate that quantitative analysis of CD34 and CD117 may be useful to detect minimal residual disease (MRD) and could be tested in a future to monitor therapy in AML...
  37. doi Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial
    David Gonzalez
    Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 29:2223-9. 2011
    ..We aimed to address the frequency and prognostic value of TP53 abnormalities in patients with CLL in the context of a prospective randomized trial...
  38. ncbi p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome
    V Brito-Babapulle
    Department of Academic Haematology Cytogenetics, Royal Marsden Hospital NHS Trust and Institute of Cancer Research, London, UK
    Br J Haematol 110:180-7. 2000
    ..Alternatively, the frequent loss of the p53 gene could be associated with the deletion of an adjacent gene, which could be involved in the pathogenesis of these diseases...
  39. ncbi Definition of acute biphenotypic leukemia
    E Matutes
    Academic Department of Hematology and Cytogenetics, Royal Marsden Hospital, London, UK
    Haematologica 82:64-6. 1997
    ..In this work we analyze diagnostic criteria for BAL...
  40. ncbi Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma
    L Hendry
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Leuk Lymphoma 45:945-50. 2004
    ..The role of FCM as first line therapy deserves study as well as its combination with the monoclonal antibody Rituximab...
  41. ncbi Morphological and immunophenotypic features of chronic lymphocytic leukemia
    E Matutes
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London, SW3 6JJ, UK
    Rev Clin Exp Hematol 4:22-47. 2000
    ..Both provide relevant information in terms of diagnosis, course of the disease, prognosis and pathogenesis...
  42. ncbi Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia
    V Brito-Babapulle
    Academic Department of Haematology and Cytogenetics Institute of Cancer Research, London, UK
    Br J Haematol 114:327-32. 2001
    ..Thus, 13q14.3 deletions could contribute to the development of overt leukaemia in T-PLL, but the involvement of more than one gene in the region cannot be excluded...
  43. ncbi Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma
    E Matutes
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Haematol 115:801-6. 2001
    ..This is the first case documented by molecular methods of the transformation of the pre-existing clone...
  44. ncbi The variant form of hairy-cell leukaemia
    E Matutes
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 16:41-56. 2003
    ..Transformation to large cell is seen in 6% of patients. The inferior survival in HCL-variant compared with typical HCL cases may reflect the chemotherapy resistance...
  45. pmc New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders
    E Matutes
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
    J Clin Pathol 55:180-3. 2002
    ..Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed...
  46. ncbi Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemia
    N Osuji
    Section of Haemato oncology, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Sutton, Surrey, UK
    Histopathology 50:547-54. 2007
    ..To augment the limited literature on bone marrow (BM) appearances in T-cell large granular lymphocyte (LGL) leukaemia and to identify a histological signature to aid in diagnosis of this condition...
  47. ncbi Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
    D Catovsky
    Section of Haemato oncology, Institute of Cancer Research, Sutton, UK
    Lancet 370:230-9. 2007
    ..We aimed to establish whether this treatment combination provided greater survival benefit than did chlorambucil or fludarabine...
  48. ncbi Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia
    E Tuset
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Leuk Lymphoma 42:1379-83. 2001
    ..The reasons for the immunophenotypic changes are unknown but it is likely that loss of CD52 antigen expression contributed to the resistance to CAMPATH-1H in one of the patients when re-treated...
  49. ncbi Teaching cases from the Royal Marsden and St Mary's Hospital case 29: striking generalized lymphadenopathy in 'acute myeloid leukemia'
    Philip Beer
    Department of Hematology, St Mary s Hospital, London, UK
    Leuk Lymphoma 46:155-6. 2005
  50. ncbi Teaching cases from the royal marsden and St Mary's Hospitals. Case 22: an unusual cause of lymphocytosis
    Ketan C Patel
    Department of Haematology, St Mary s Hospital, London, UK
    Leuk Lymphoma 43:923-5. 2002
  51. ncbi Alemtuzumab in T-cell malignancies
    Claire E Dearden
    St George s Hospital Medical School, London, UK
    Med Oncol 19:S27-32. 2002
    ..We conclude that treatment with alemtuzumab may offer new hope to patients who otherwise have a bleak prognosis...
  52. ncbi Prolonged treatment response in aggressive natural killer cell leukemia
    N Osuji
    Section of Haemato oncology, Royal Marsden NHS Trust Institute of Cancer Research, London, UK
    Leuk Lymphoma 46:757-63. 2005
    ....
  53. doi Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper
    M Dungarwalla
    Haemato Oncology Unit, The Royal Marsden Hospital, London, UK
    Eur J Haematol 80:469-76. 2008
    ..While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant...
  54. ncbi Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia
    I A Astsaturov
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London, UK
    Leukemia 10:769-73. 1996
    ..B29 (CD79b) is present in the membrane at a later stage compared to its cytoplasmic expression and found in mature B blasts (B-ALL) that express membrane Ig as it is in normal and leukaemic B lymphocytes...
  55. ncbi High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Ann Hematol 82:759-65. 2003
    ..This study demonstrates that HDMP alone or in combination with other agents is a useful treatment strategy in refractory CLL including patients with p53 abnormalities...
  56. ncbi Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene
    Alicja M Gruszka-Westwood
    Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, UK
    Genes Chromosomes Cancer 33:206-12. 2002
    ..This is to our knowledge the first description of amplification of the CCND1/IGH fusion gene in a human neoplasm, which may have played a role in the fulminating course of the disease in this patient...
  57. ncbi Chronic T-cell lymphoproliferative disorders
    Estella Matutes
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, The Royal Marsden Hospital, London, UK
    Rev Clin Exp Hematol 6:401-20; discussion 449-50. 2002
  58. ncbi Prolymphocytic leukemias
    Biju Krishnan
    Department of Haemato Oncology, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Semin Oncol 33:257-63. 2006
    ..In particular, the use of Campath-1H, in T-PLL has more than doubled median survival. The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored further...
  59. doi A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia
    Maria Chiara Di Bernardo
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 40:1204-10. 2008
    ..32 (rs11083846, PRKD2; P = 3.96 x 10(-9)). These data provide the first evidence for the existence of common, low-penetrance susceptibility to a hematological malignancy and new insights into disease causation in CLL...
  60. ncbi Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia
    Martin Yuille
    Academic Department of Haematology and Cytogenetics, and the Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 99:4216-8. 2002
    ..04). The risk of CLL associated with possession of all 3 "high-risk" genotypes was increased 2.8-fold (OR = 2.8, 95% confidence interval: 1.1-6.9). Our findings suggest that heritable GST status may influence the risk of developing CLL...
  61. pmc Deoxycoformycin in the treatment of mature T-cell leukaemias
    C Dearden
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, UK
    Br J Cancer 64:903-6. 1991
    ..We conclude that DCF is a useful therapy for the treatment of T-cell leukaemias, in particular Sezary syndrome and T-PLL, and should play a part in strategies to improve the natural history of this group of lymphoid malignancies...
  62. pmc A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders
    S P Sah
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, 203 Fulham Road, London SW3 6JJ, UK
    J Clin Pathol 56:129-32. 2003
    ..To evaluate the diagnostic value of bone marrow aspirates, trephine biopsies (BMB), and flow cytometry (FC) in the assessment of bone marrow infiltration in chronic lymphoid disorders...
  63. doi High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis
    M Dungarwalla
    Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, UK
    Br J Haematol 143:71-4. 2008
    ..03). While transformation in the bone marrow is frequently refractory to therapy and associated with poor outcome in SMZL, lymph node transformation responds well to chemotherapy with durable progression-free and overall survival...
  64. ncbi Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies
    M O Elnenaei
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research and Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Leuk Res 25:115-23. 2001
    ..We concluded that the detection of cyclin D1 expression by flow cytometry in cell suspensions could be applied routinely to the study of B-lymphoproliferative disorders and may be of value for their diagnosis and management...
  65. ncbi Teaching cases from the Royal Marsden and St Mary's Hospitals case 25. A young boy with massive bilateral renal enlargement
    Claire Hemmaway
    Department of Haematology, St Mary s Hospital, Praed Street, London, W2 1NY, UK
    Leuk Lymphoma 45:1301-3. 2004
  66. ncbi Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif
    Paul S Bradshaw
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, UK
    Oncogene 21:483-7. 2002
    ..The structures of the ATM duplications suggest they may arise from an error in somatic hypermutation. We suggest that aberrant components of somatic hypermutation may contribute to the defective DSB repair characteristic of cancer...
  67. ncbi First report of fludarabine in gamma-heavy chain disease
    S Agrawal
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London
    Br J Haematol 88:653-5. 1994
    ..This response has, so far, been sustained for 2 1/2 years after stopping treatment...
  68. ncbi Acute erythroid leukemia (M6): outcome of bone marrow transplantation
    S Killick
    Leukaemia Unit, The Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
    Leuk Lymphoma 35:99-107. 1999
    ..The disease is sensitive to AML induction regimens and long-term survival can be achieved with BMT in first complete remission...
  69. ncbi Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia
    M Dungerwalla
    Section of Haemato oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
    Br J Haematol 130:511-5. 2005
    ..We also describe objective response to antiviral therapy. To our knowledge, this is the first report of such presentation and response...
  70. ncbi ATM is usually rearranged in T-cell prolymphocytic leukaemia
    M A Yuille
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research Royal Marsden Hospital NHS Trust, London, UK
    Oncogene 16:789-96. 1998
    ..The mechanism of inactivation appeared to be unusual because multiple structural lesions on one allele were often observed...
  71. ncbi Lymphopain, a cytotoxic T and natural killer cell-associated cysteine proteinase
    J Brown
    Leukaemia Research Fund Centre at the Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Leukemia 12:1771-81. 1998
    ..The cellular distribution of lymphopain expression, together with the functional demonstration of lymphopain-associated proteinase activity in vitro, is suggestive of a role for lymphopain in immune cell-mediated, cell killing...
  72. ncbi Prospective study of HTLV-I infection in an initially asymptomatic cohort
    G P Taylor
    Clinical Trials Centre, Imperial College School of Medicine, St Mary s Hospital, London, UK
    J Acquir Immune Defic Syndr 22:92-100. 1999
    ..Persistently high proviral load appears to predate the development of HTLV-I-associated inflammation in neuro-ophthalmic tissue...
  73. ncbi Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history
    G S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Leuk Lymphoma 48:1320-2. 2007
    ..In conclusion, our study demonstrates that MSI does not have a prominent role in the pathogenesis of B-CLL...
  74. ncbi Chromosomal imbalances in familial chronic lymphocytic leukaemia: a comparative genomic hybridisation analysis
    B Summersgill
    UK Co ordinating Centre for the Study of Familial Chronic Lymphocytic Leukaemia, Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, UK
    Leukemia 16:1229-32. 2002
    ..This suggests these regions may harbour a susceptibility locus for CLL. There is also some evidence that chromosome regions 2p12-p14 and 4q11-q21 may harbour predisposition genes...
  75. ncbi Response to cyclosporine in a patient with disseminated granuloma annulare associated with CD4+/CD8+(dim)/CD56+ large granular lymphocytic leukemia
    Elisa Granjo
    Arch Dermatol 138:274-6. 2002
  76. ncbi The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia
    Monica Else
    Section of Haemato oncology, Royal Marsden Hospital Institute of Cancer Research, Sutton, United Kingdom
    Cancer 110:2240-7. 2007
    ..They continue to be effective at second- and even third-line therapy; however, alternative treatments are needed for patients who are or have become refractory to these agents or whose remissions are shorter with each course of therapy...
  77. ncbi The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
    Claire Dearden
    Royal Marsden National Health Service NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Blood 111:1820-6. 2008
    ..In conclusion, DAT status at the time of initiation of therapy provides a new prognostic indicator, although FC may protect against AHA. This trial was registered at http://isrctn.org as no. 58585610...
  78. ncbi The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases
    Yang O Huh
    Department of Hematopathology, MD Anderson Cancer Centre, The University of Texas, Houston, TX 77030, USA
    Br J Haematol 136:220-8. 2007
    ..However, these neoplasms also differ from CLL cytologically and in their immunophenotype...
  79. ncbi Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, University of Leeds, HMDS, West Yorkshire, Surrey, United Kingdom
    Blood 100:2289-90. 2002
    ..The detection of CLL-phenotype cells provides a surrogate marker of carrier status, potentially facilitating gene identification through mapping in families and direct analysis of isolated CLL-phenotype cells...
  80. ncbi A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
    Jenny Orchard
    Department of Haematology, Royal Bournemouth Hospital, United Kingdom
    Blood 101:4975-81. 2003
    ..We find no evidence against a diagnosis of MCL in the nonnodal group and suggest that mutated IgVH genes may help identify patients with indolent disease...
  81. ncbi [Chronic lymphoproliferative syndromes in Chile. A prospective study in 132 patients]
    Maria Elena Cabrera
    Departamento de Medicina, Campus Oriente, Facultad de Medicina, Universidad de Chile, Servicio de Medicina, Hospital del Salvador, Santiago
    Rev Med Chil 131:291-8. 2003
    ..Chronic lymphoproliferative disorders include a variety of diseases which are often a diagnostic problem for clinical hematologists...
  82. pmc Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations
    Anne Tierens
    Departments of Pathology and Tumor Biology, The Norwegian Cancer Institute and Radiumhospital, University of Oslo, Oslo, Norway
    Am J Pathol 162:681-9. 2003
    ..Our results indicate that marginal zone lymphomas at different anatomical localizations may derive from a similar B-cell subset...
  83. ncbi Alemtuzumab in T-cell lymphoproliferative disorders
    Claire E Dearden
    Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Best Pract Res Clin Haematol 19:795-810. 2006
    ....
  84. ncbi Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years
    Monica Else
    Section of Haemato oncology, Royal Marsden NHS Foundation Trust Institute of Cancer Research ICR, Sutton, United Kingdom
    Cancer 104:2442-8. 2005
    ..Both pentostatin and cladribine have efficacy in hairy cell leukemia (HCL), but it is not known which agent achieves better results...
  85. ncbi Intraclonal diversity in a Sezary syndrome with a differential response to 2-deoxycoformycin of the two lymphoma cell populations
    Elisa Granjo
    Department of Clinical Haematology, Hospital Geral de São João, Porto, Portugal
    Br J Haematol 119:629-33. 2002
    ....
  86. ncbi Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia
    Ilaria del Giudice
    Section of Hemato Oncology, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer 104:2124-32. 2005
    ....
  87. ncbi Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization
    Claus L Andersen
    Department of Hematology, Laboratory of Cancer Cytogenetics, Arhus Sygehus, Tage Hansens Gade 2, DK 8000 Arhus C, Denmark
    Cancer Genet Cytogenet 156:122-8. 2005
    ..Our data suggest that SMZL constitute a genetically heterogeneous disease where gain of 3q25 and loss of 7q31 are the most likely imbalances to be involved in the pathogenesis of the disease...
  88. ncbi The WHO classification of mature T-cell leukemias
    Daniel Catovsky
    Blood 104:2989-90; author reply 2990. 2004
  89. ncbi The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey
    Cancer Epidemiol Biomarkers Prev 13:1065-7. 2004
    ..80-1.31). A meta-analysis of this study and five other smaller published studies provides no evidence of relationship between this P2X7 polymorphism and risk of CLL (odds ratio = 0.99, 95% confidence interval: 0.74-1.32)...
  90. ncbi MTHFR polymorphisms and risk of chronic lymphocytic leukemia
    Matthew F Rudd
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    Cancer Epidemiol Biomarkers Prev 13:2268-70. 2004
    ..97 (95% CI, 0.79-1.18) and 0.88 (95% CI, 0.62-1.24), respectively. This data indicate that the MTHFR polymorphisms C677T and A1298C do not significantly contribute to an inherited genetic susceptibility to CLL...
  91. ncbi Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
    Donald W Milligan
    Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom
    Blood 105:397-404. 2005
    ..Detectable molecular disease by PCR was highly predictive of disease recurrence. It is of concern that 5 of 65 (8%) patients developed posttransplant acute myeloid leukemia/myelodysplastic syndrome...
  92. pmc Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma
    Gunhild Trøen
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello N 0310, Oslo, Norway
    J Mol Diagn 6:297-307. 2004
    ....
  93. ncbi Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom
    Blood 111:5691-3. 2008
    ..These observations provide evidence that familial CLL is essentially indistinguishable from sporadic CLL, favoring a genetic basis to disease development in general rather than a simple environmental etiology...
  94. ncbi Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia
    Ilaria del Giudice
    Haematologica 90:268-70. 2005
    ..During follow-up post-treatment, seven delayed responses (54%) were observed, improving the initial overall response rate of 61% to a final response rate of 77%...
  95. ncbi Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia
    Nnenna Osuji
    Section of Haemato oncology, Royal Marsden NHS Foundation Trust Institute of Cancer Research, Surrey SM2 5PT, UK
    Br J Haematol 128:645-8. 2005
    ..Pregnancy thus appears to have a beneficial effect on neutrophil count in T-cell LGL leukaemia...
  96. ncbi Delineation of the minimal region of loss at 13q14 in multiple myeloma
    Manal O Elnenaei
    Department of Academic Haematology and Cytogenetics, The Institute of Cancer Research and Royal Marsden NHS Trust, London, United Kingdom
    Genes Chromosomes Cancer 36:99-106. 2003
    ..However, a role for RFP2 in the pathogenesis of MM cannot yet be excluded, given that alternative mechanisms such as haploinsufficiency remain possible...
  97. pmc A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom
    Am J Hum Genet 77:420-9. 2005
    ..01). None of the regions coincided with areas of common chromosomal abnormalities frequently observed for CLL. These findings strengthen the argument for an inherited predisposition to CLL and related B-cell LPDs...
  98. ncbi The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53
    Nnenna C Osuji
    Haematologica 90:1435-6. 2005
    ..214). We confirm the efficacy of alemtuzumab in refractory CLL irrespective of p53 deletions, and advocate its introduction earlier in disease course...
  99. ncbi High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia
    Donald W Milligan
    Department of Haematology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK
    Br J Haematol 133:173-5. 2006
    ..4% (95% confidence interval, 2.5-24%). No analysed potential risk factor was predictive for MDS/AML development. We hypothesise that potential causative factors are fludarabine, low cell dose and transplant conditioning...
  100. ncbi p53 and mdm2 in mantle cell lymphoma in leukemic phase
    Max Solenthaler
    Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland
    Haematologica 87:1141-50. 2002
    ..This study aimed to assess the frequency, relationship and impact of p53 abnormalities and those of its inhibitor mdm2 in blastoid and non-blastoid MCL in leukemic phase...
  101. doi High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
    Moez Dungarwalla
    Haematologica 93:475-6. 2008
    ..Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections...